Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020 September 20, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position delivering a positive EBITDA profit of £2.1 million compared to an EBITDA loss of £4.1 million in H1 2020. We…

Continue reading

Open Orphan #ORPH – Pfizer successful Phase 2a human challenge trial August 2, 2021 – Posted in: Blog, Open Orphan (ORPH)

Rapid progress at Open Orphan #ORPH. In Pfizer’s recent quarterly update, CEO Albert Bourla, noted (on page 5) that one of the key highlights of Pfizer’s Q2 was the “Successful Phase 2a human challenge trial with RSV Adult vaccine candidate”. Although Pfizer have not mentioned Open Orphan by name and we have not formally announced our involvement, hVIVO is listed as the sponsor to the study here and with hVIVO contact details noted on the Pfizer…

Continue reading

Open Orphan (ORPH) Final Results to 31 December 2020 June 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Final Results to 31 December 2020 Important year of transition following the various merger and acquisition activities in 2019 and January 2020 Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its audited results for the 12 months to 31 December 2020. Following the acquisition of hVIVO in January of last year, 2020 was a…

Continue reading

Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies December 7, 2020 – Posted in: Open Orphan (ORPH)

Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies Pharmaceutical companies worldwide are joining global efforts to combat, diagnose, treat and prevent infections from COVID-19. As we have seen, the search for vaccines and possible treatment to curb the transmission and reduce the mortality and morbidity produced by the virus is in overdrive. Link here to read the full article…  

Continue reading

The Sun – COVID-19: UK scientists to infect volunteers with coronavirus in world first vaccine trial November 25, 2020 – Posted in: Open Orphan (ORPH)

Would you lock yourself in a room for two weeks after being infected with COVID-19? Chris Holdsworth did, and he hopes that come January that’s exactly what he’ll be doing. Chris has volunteered to be a guinea pig for a world-first study that could take place in the UK in January. It’s called a Human Challenge Trial, and it involves shutting healthy volunteers in an isolation unit like this one and deliberately infecting them with…

Continue reading

Most people try to avoid Covid-19. But thousands are signing up to be deliberately exposed – CNN October 12, 2020 – Posted in: Open Orphan (ORPH)

By Mick Krever, Phil Black and Cristiana Moisescu, London (CNN) – As most of us obsess with avoiding Covid-19 at all costs, a rapidly growing group of people around the world say they are prepared to deliberately take on the virus. Tens of thousands of people have signed up to a campaign by a group called 1 Day Sooner to take an experimental vaccine candidate and then face coronavirus in a controlled setting. Among them is…

Continue reading